Life Sciences Archive » May, 2024

Life Sciences - May, 2024

272 articles

• Caremark Cut Loose From CVS Price-Gouging Case
• Samsung Strikes First With Smart Ring IP Suit Against Oura
• PTAB Upholds Medtronic Bladder Control Patents On Remand
• COVID Test Contract Suit 'Cries Out' For Jury, NC Judge Says
• 9th Circ. COVID 'Cure' Case Shows Perks Of Puffery Defense
• FTC Focus: Exploring The Meaning Of Orange Book Letters
• Weight Loss Drug Caused Stomach Paralysis, Suit Says
• Beasley Allen Wants J&J Subpoenas Nixed Amid Ethics Fight
• New Antibody IP Ruling Still Needs To Be Tested In Courts
• Investors Can Aid In The Acceptance Of Psychedelic Medicine
• In Rarity, 1 Party's Judges Gain 100% Control Of Circuit Bench
• FDA Seeks Fines Over Elf Bar E-Cigarette Sales
• Warren Pushes To Clinch 'Popular' Drug Patent 'March-In' Plan
• Exec Found Liable For 'Shadow Trading' Seeks New Trial
• Rite Aid Ch. 11 Timeline Extended To Allow More Plan Review
• 'South Park'-Quoting Judge Says CEO Can't 'Blame Canada'
• What To Watch As The FTC Targets Drug Patent Listings
• Class Actions At The Circuit Courts: May Lessons
• Pa. Court Blocks State's Recall Over Cannabis Vape Additives
• Ozempic Maker Says Texas Pharmacy Selling Knockoff Drug
• Trauma-Informed Legal Approaches For Pro Bono Attorneys
• 3M Nixes Teva Inhaler Patent On Appeal At EPO
• Ex-Sidley Atty To Lead Faegre's West Coast Class Action Team
• NY Attys Back Bid For Justices To Hear Double-Patenting Row
• South Baltimore Citizens Call On EPA For Incinerator Relief
• FDA Sued Over Controversial Lab Test Rule
• Israeli Nanotech Startup, Canadian Biotech Plot US IPOs
• Chicago IP Firm Accused Of Botching Fetal Biotech Patent
• Wilson Sonsini Adds 2 Attys In Salt Lake City From Kirkland
• Gibson Dunn, Skadden Guide $3B Merck-EyeBio Deal
• 3 Firms Build $627M Take-Private Sale Of Medical Device Biz
• Greenberg Traurig Adds IP Atty From Eversheds Sutherland
• Whistleblower Counsel Can't Get 'Exorbitant' $11.5M Fee
• Playing Music Makes Me A Better Lawyer
• Abbott, Dexcom Call For New Glucose Monitor Patent Trial
• J&J To Pay $1.25B For Global Rights To Eczema Treatment
• HIV Drug Buyers Fight Bid To Combine 9th Circ. Appeal Briefs
• Catching Up With Delaware's Chancery Court
• Ga. Dental Imaging Co. Fights To Keep X-Ray IP Suit Alive
• Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
• Beasley Allen, J&J Trade Barbs Over DQ Bid In Talc Litigation
• Proposed Cannabis Reschedule Sidesteps State Law Effects
• How Attys Can Avoid Pitfalls When Withdrawing From A Case
• Esperion Launches Suits Over Cholesterol Drug Patents
• Treaty Wants Patents To Cite Ties To 'Traditional Knowledge'
• Petition Watch: Forum Shopping, Monopolies & Gun Safety
• Fla. Lab Owner Will Pay $27M To End False Billing Suit
• Shuttered Paper Mill Flouted $12M Incentive Deal, NC AG Says
• NY AG Sues Over Illegal Long Island Wetland Construction
• Biden's Judicial Impact And What's Left On The Wish List
• NYSE Companies Could Face Heat If Business Focus Changes
• UK Litigation Roundup: Here's What You Missed In London
• Using A Children's Book Approach In Firm Marketing Content
• NJ Justices Toss Direct Appeals Over Hospital Contract Bid
• Fed. Circ. Upends Inventors' Interference Win Over Time-Bar
• A Changing Regulatory Landscape For Weight Loss Drugs
• Opioid Suits Offer Case Study In Abatement Expert Testimony
• Ex-Judge Pushed False Narrative On Atty Romance, Firm Says
• Patent Lessons From 4 Federal Circuit Reversals In April
• Merck To Pay $600M For KKR-Backed Life Sciences Biz
• Just 57% Of Complex Global Deals Closed Since 2020
• J&J Loses Expedited Bid For Beasley Allen Docs In Talc MDL
• GSK, Boehringer Prevail In 1st Zantac Cancer Trial
• Inventor To Take $102M IP Malpractice Row To Ga. High Court
• Cancer Patients Target J&J Talc Unit's Asset Shuffles
• Justices' CFPB Alliance May Save SEC Courts, Not Chevron
• FDA Must Act On Sexual Side Effects Of SSRIs, Suit Says
• USPTO's Proposed Disclaimer Rule Would Harm Inventors
• Evidence Shaky In First Zantac Cancer Trial, Drugmakers Say
• Doc Gets 3 Mos. For Alexion Trades Despite 'Meaningful Job'
• DuPont 'Document Dump' Rattles NC In PFAS Suit
• Stryker Agrees To Settle Calif. Misclassification Suit
• MilliporeSigma Avoids Charges As DOJ Extols Self-Disclosure
• Teva, Bristol-Myers Cite Bystolic Against Cancer Drug Case
• Being An EMT Makes Me A Better Lawyer
• Dickinson Adds Ex-Sheppard Mullin IP Pro In Silicon Valley
• Lead Blood Test Maker To Plead Guilty, Pay $42M Over Defects
• Covington Reps As Biogen Makes $1.8B Bet On HI-Bio
• Hawaii Wins $916M From Bristol-Myers, Sanofi Over Plavix
• Ex-AUSA Blames Inexperience For Outcome Forfeiture Error
• Sens. Challenge Pharma Lobbyist Over Patent Abuse
• DC Circ. Says Drugmakers Can Limit Pharmacy Discounts
• MetLife Workers Tell 3rd Circ. Higher Premiums Give Standing
• CohnReznick Adds PwC Partner To International Tax Practice
• SPAC Investor's Suit Changes Came Too Late, Chancery Rules
• PE Firms Close Separate Funds With Nearly $1.3B Total In Tow
• Cooley Atty Returns From Deputy GC In-House Role In Boston
• Strategic Hiring Was The New Normal For BigLaw In 2023
• The Law360 400: Tracking The Largest US Law Firms
• Paul Hastings' FDA Chair Departs For Arnold & Porter
• Ex-IRS Agent, Five Others Sentenced In COVID Fraud Scheme
• Lab Says GSK Hid Zantac Cancer Risk From Feds For Decades
• Teladoc Faces Suit Over Mental Health Platform's Losses
• Ultragenyx Must Face Suit Over Use Of Henrietta Lacks' Cells
• USPTO Clarifies Means-Plus-Function Claims For Antibodies
• McKinsey Can't Nix Pregnant Women's Claims In Opioid MDL
• Judge Tosses Acuitas' COVID Biotech IP Suit
• Local Governments Seek Sanctions For PBMs In Opioid MDL
• iRhythm Brass Face Suit Over FDA's Heart Monitor Inquiry
• Mitigating Incarceration's Impacts On Foreign Nationals
• Contract Disputes Recap: Saying What Needs To Be Said
• J&J Says Beasley Allen Looking To 'Bias' Vote On $6.5B Plan
• Latham Hires 2 Skadden Healthcare Partners In DC
• Catching Up With Delaware's Chancery Court
• Ga. Judge OKs $5M Atty Fees In $41M Acella Thyroid Deal
• Moderna Fends Off Pfizer's MRNA Patent Challenge
• Shah Ends Novavax Proxy Fight Following Sanofi Deal
• VA Deal Winner Says Protest Not Based On Common Sense
• Allergan Says Deserted Drug Rule Weakens $680M Fraud Suit
• Patent Office Gets Another Earful About 'March-In' Plan
• Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca
• FCA Relators Seek Finders Fee For SpineFrontier Doc Deals
• Judge Won't Bar Thermo Fisher Exec's Jump To Repligen
• EndoStim Emerges From Delaware Insolvency Proceeding
• Industry Emboldened After Justices Galvanize Agency Attacks
• Texas Justices Let Fen-Phen Atty Malpractice Fight Roll On
• Winston & Strawn Leads Asia-Focused SPAC $100M IPO
• UK Litigation Roundup: Here's What You Missed In London
• Ointment Scheme Conned Gov't Out Of Millions, Fla. Suit Says
• 3rd Circ. Shuns Teva's 'Novel' Appeal On Israeli Investor Class
• FTC Deputy Director Rao On Healthcare Antitrust Agenda
• NJ Judge Scrutinizes J&J Unit's Libel Claim Over Talc Study
• IQVIA To Pay $3.5M To Resolve Ex-Workers' 401(k) Suit
• Ex-Pharma Exec Cops To Contempt For Barred Finance Work
• Gilead, Teva Want 17 HIV Drug Antitrust Appeals Consolidated
• Lessons On Challenging Class Plaintiffs' Expert Testimony
• Exploring An Alternative Model Of Litigation Finance
• Pa. Pot Co. Says No Deal To Breach In Growth IP Suit
• $5.5M Apotex Generic Drug Price-Fixing Deal Gets Initial OK
• Del. IP Ruling May Mark Limitation-By-Limitation Analysis Shift
• HUD Calls Pa. Medical Marijuana Housing Suit Premature
• Biden Admin Proposes To Loosen Restrictions On Marijuana
• 'Excellent' Altria MDL Deal Earns Attys Fees Above Benchmark
• Lilly Lands Default ITC Order Against Weight Loss Copycats
• Feds, Pesticide Cos. Seek More Time To Find Mediator
• Anthem Blue Cross Owes $3.8M For COVID Tests, Lab Says
• Cell Therapy Cos. Must Beware Limits Of Patent Safe Harbors
• AstraZeneca Sales Reps Win Early Cert. In Gender Bias Suit
• Monsanto's $23M False Ad Deal Challenged At 9th Circ.
• Former Sandoz Executive Avoids Prison In Price-Fixing Case
• Teaching Yoga Makes Me A Better Lawyer
• How Clinical Trials Affect Patentability In US And Europe
• Biotech Co. Sued In Del. For Faulty Election, Share Hike Vote
• The PREP Immunity Question Won't Be Decided Yet
• Norwich, Bausch Ask Fed. Circ. To Rethink Xifaxan IP Ruling
• Calif. City Sues Dow, Shell Over TCP-Tainted Water
• Vein Tech Maker Faces Investor Suit Over DOJ Kickback Probe
• Jury's $2M Medical Device Infringement Verdict Upended
• States Accuse EEOC Of 'Smuggling' Abortion Into PWFA Rule
• Biotech Co. Hits Bankruptcy With Creditor Deal In Hand
• Congressional IP Attorneys Keeping Close Watch On AI
• Mich. AG Says Eli Lilly 'Cherry-Picking' Enforcement Data
• A Vision For Economic Clerkships In The Legal System
• Shire Settles Claims Over Alleged ADHD Generic Delay
• State-Regulated Cannabis Can Thrive Without Section 280E
• Key Takeaways From FDA Final Rule On Lab-Developed Tests
• Chinese Drug Co. Sanctioned After 'Tortuous' 3-Year Info Fight
• USPTO Eyes Change To Patent Applicants' Disclaimer Practice
• Biogen Investors Seek Class Cert. In Alzheimer's Drug Suit
• 2nd Circ. Affirms Dismissal Of Bystolic Antitrust Suit
• SEC Says Biotech Co., Atty Should Pay $14M For Investor Lies
• Assessing HHS' Stance On Rare Disease Patient Assistance
• Ga. Dental Imaging Co. Pushes For Ax Of X-Ray IP Row
• Ex-Police Chief Gets 3 Months For Alexion Insider Trading
• Calif. Jury Awards Ex-UCLA Doctor $14M In 2nd Bias Trial
• Philips Wants Cleaner Co. To Chip In For $1B CPAP Deal
• Feds' Biotech Enforcement Efforts Are Too Heavy-Handed
• McCarter & English Aims To Sink Biotech Malpractice Suit
• 'Prolific' Asbestos Injury Firm Accused Of Fraud, Racketeering
• Haynes Boone Lands Procopio Life Sciences Leader In Calif.
• Retail Group Opposes $1B Arbitral Award Against Walgreens
• Pharma Cos., FDA Debate 'Same Drug' In Orphan Drug Case
• Lab Exec Sentenced For Deadly Fungal Meningitis Outbreak
• Pharmaceutical Cos. Can't Nix Parkinson's Drug Antitrust Suit
• Regulating Resurrected Species Under The ESA
• E-Discovery Quarterly: Recent Rulings On Text Message Data
• What CRA Deadline Means For Biden Admin. Rulemaking
• Fox Rothschild Hires Ex-Seed IP Trio On The West Coast
• No 'Piecemeal' Fees For Infant Data Win Amid 6th Circ. Appeal
• Sanofi, Novavax Sign $1.2B Deal For One-Shot COVID, Flu Jab
• Fed. Circ. Lifts Ban On Generic Cos.' Bladder Drugs
• Judge Clarifies Gilead Didn't Directly Infringe HIV Drug IP
• First Zantac Trial Plaintiff Says She Can't Live Normal Life
• Judge Halts DEA's Hearing On Proposed Psychedelics Ban
• Masimo Makes Offer To End Activist Politan's Proxy Contest
• Fed. Circ. Skeptical Allergan Illegally Extended Exclusivity
• 5 Takeaways From FDA's Biosimilars Promotion Guidance
• Ex-Dental Device CEO Cops To $10.7M Investor Fraud
• Ex-Official Says NJ, Ethics Board Are 'Stonewalling' Discovery
• Dual-Track IPO-M&A Exit Strategies For Life Science Cos.
• Body-Sculpting Device Supplier Hit With Fraud Claims
• 11th Circ. Rejects Monsanto's Roundup Suit Redo Request
• Does Expert Testimony Aid Preliminary IPR Responses?
• Ex-Pharma Exec Asks 1st Circ. To DQ Judge In Contempt Case
• Apnea Device Maker ProSomnus Gets OK For Ch. 11 Loan
• Deals Rumor Mill: Paramount, Peloton, International Paper
• Quinn Emanuel Atty Says Asset Freeze Hurt Outcome Defense
• Opioid Maker Beats Investor Suit Over FDA Warning For Good
• Are Concessions In FDA's Lab-Developed Tests Rule Enough?
• Shockwave Medical Investor Challenges $13B Deal With J&J
• Conn. Justices To Hear McCarter & English Damages Demand
• Kirkland Drives Vance Street To $775M Fund IV Closing
• Double-Patenting Ruling Shows Terminal Disclaimers' Value
• Swimming Makes Me A Better Lawyer
• Sleep Apnea Co. Hits Ch. 11 Over $41.5M In Debt, Cash Woes
• Simpson Thacher-Led Silver Lake Lands $20.5B For 7th Fund
• GOP Reps. Want IP Enforcers To Get Tougher On Infringers
• Iceberg Image Closes Pacira Drug Patent Infringement Trial
• Pharma Co. Falsely Touted Obesity Drug Results, Suit Claims
• Fed. Circ. Seems Wary Of Broad's CRISPR Inventorship Win
• Colo. Judge Tells Cos. Their Warring Briefs Aren't Helping
• Mid-2024 FCA Enforcement And Litigation Trends To Watch
• Fla. Schools And Hospitals Fight To Save Opioid Claims
• Gov't Seeks Early Win In Ga. Medicaid Expansion Suit
• NJ Law Firm Scores Exit In Benicar MDL Fees Suit
• Prepetition Waivers Sway Invitae Judge On Kirkland Hire
• 1st Circ. Questions SEC Walk-Back In Conn. Atty's Fraud Case
• What 100 Federal Cases Suggest About Changes To Chevron
• Law Firm Must Face COVID Test-Kit Fraud Suit, NJ Court Told
• Birth Control Cos. Can't Dodge Conn. Injury Suit, Court Told
• US Thrashes Mexico's 'Inaccurate' Portrayal Of GMO Corn
• Biotech Co. Wants To Appeal Red Cross Antitrust Immunity
• Warranty Claims Trimmed From Bone Graft Tuberculosis Suit
• Chickasaw Can't Reopen Optum Prescription Payback Suit
• Paul Weiss Lands M&A Pro Who Sees Strong Deals Pipeline
• Why High Court May Have Rejected IP Obviousness Appeal
• Catching Up With Delaware's Chancery Court
• SEC Settles Insider Info Charges With CBD Co.'s Ex-Chairman
• Microplastics At The Crossroads Of Regulation And Litigation
• Mintz Adds Proskauer Life Sciences IP Litigation Team
• Ala. High Court Won't Rethink Decision On Frozen Embryos
• FTC Requests Additional Info On $16.5B Novo-Catalent Deal
• Publix Can't Send Questions To Ga. Justices In Opioid Suit
• Medical Testing Co. Not In Health Field For Taxes, IRS Says
• 4th Circ. Preview: Hemp, Wells And A Withdrawal
• UK Litigation Roundup: Here's What You Missed In London
• The Fed. Circ. In April: Hurdles Remain For Generics
• 6 States Strike $270M Opioid Deal With Amneal
• 7th Circ. Mostly Backs Ill. Home Health Kickbacks Judgment
• Endo Judge Hopes Criminal Sentence Warns Opioid Makers
• Walgreens Fights $1B Arb. Award Over COVID Test Contract
• Feds Call Out Gilead's Efforts To Revise HIV Drug IP Judgment
• Masimo Hit With Derivative Suit Over Audio Co. Acquisition
• Latham, Skadden Grab Spotlight As Large IPOs Surge In April
• Email Exchanges Doom Honeywell Bid To Nix $20M GSA Claim
• Pharma. Co. Wants Ex-Director To Stop Poaching Customers
• Calif. Justices To Review Gilead's HIV Drug Negligence Fight
• State Legislators Urge Feds To Change Cannabis' Status
• Tylenol MDL Highlights Expert Admissibility Headaches
• Recent BigLaw Moves Show Boston Is 'Clearly On The Map'
• 4th Circ. Revives Workers' Suit Over SC Plant Explosion
• Schumer Reups Call For His Judge Shopping Bill
• Plaintiff To Share 'Horrific' Story In First Zantac Cancer Trial
• Skin Care Drug Co. Gets OK For Ch. 11 Wind-Down Plan
• Freshfields-Led Novartis Inks $1.75B Cancer Drug Co. Buyout
• Don't Use The Same Template For Every Client Alert
• 3 Takeaways From The DOJ's Cannabis Recommendation
• Dental Supply Co. Must Face Suit Over COVID-Era Woes
• Bayer Can't Scratch Off Antitrust Suit Over Flea, Tick Meds
• Median Patent Damages Awards Are Shrinking
• Eiger Gets Deal With Merck Over $46M Rare-Disease Drug Sale
• 3rd Circ. Flags Bayer's Knowledge Of Tainted Fungal Spray
• 'Foul' BioVentrix Cash-Out Gets Extra Scrutiny, Chancery Says
• J&J Unit Cuts Deal To End Cancer Drug Trade Secret Fight
• 5th Circ. Judge Skeptical Of Medicare Drug 'Price-Setting'
• Don't Fall On That Hill: Keys To Testifying Before Congress
• Online Portal Helps Fortify Feds' Unfair Health Practices Fight
• Insulin Pump Maker Wins Toss of Investor Suit For Now
• Attys Say $5M Fee In Acella Settlement A Modest Proposal
• AI Is Top Of Mind For Companies — And Securities Regulators
• Walking With My Dog Makes Me A Better Lawyer
• J&J Proposes $6.5B Deal To End Ovarian Cancer Claims